Developer docs
API playgroundTry for free, no card

Search company profiles

Centrexion Therapeutics

Full company profile

uuid0000kwd

Namestring
Centrexion Therapeutics
Legal namestring
Centrexion Therapeutics Corp.
Websiteurl
centrexion.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Centrexion Therapeutics is a privately held, late clinical-stage biopharmaceutical company founded in 2013 and headquartered at One Boston Place in Boston, Massachusetts. The company is developing a diversified pipeline of novel, non-opioid clinical-stage medicines intended to treat chronic pain by targeting the underlying pathophysiology of pain with specificity to both type and source. It has subsequently expanded into immunology and inflammation, pursuing differentiated therapies for autoimmune diseases characterized by high unmet medical need. Specific drug candidates are not publicly disclosed on the company website, though the pipeline is described as multiple drug candidates at various clinical stages.

The company is led by an experienced biopharmaceutical management team, including former Pfizer Chairman and CEO Jeffrey B. Kindler as CEO, Celgene founder Sol Barer, Ph.D. as Chairman, and Johns Hopkins Professor Emeritus of Neurosurgery James N. Campbell, M.D. as President and Chief Scientific Officer. In 2025 the company transitioned its Chief Medical Officer role, with Randall Stevens, M.D. moving to Chief Medical Strategist and Charles Oh, M.D. joining as CMO. Centrexion maintains strategic co-development partnerships with Eli Lilly, Boehringer Ingelheim, NIH, and Sanofi, and has cumulatively raised approximately $229 million across 12 funding rounds from 2013 through 2020, with investors including New Enterprise Associates, InterWest Partners, 6 Dimensions Capital, ArrowMark Partners, Quan Capital, EFung Capital, Exome Asset Management, and SLR Capital Partners.

Centrexion operates with 11–50 employees and currently serves the United States only. As a clinical-stage company with no approved or commercialized products, it has no disclosed revenue; its business model relies on equity and debt capital to fund R&D, with future commercialization expected to occur via pharmaceutical partnerships and standard pharmaceutical supply chains post-regulatory approval. Pricing of pipeline therapies is not publicly disclosed.

Short descriptiontext

Centrexion Therapeutics is a privately held, late clinical-stage biopharmaceutical company developing novel non-opioid therapies for chronic pain and immunology medicines for autoimmune diseases, with partnerships including Eli Lilly, Boehringer Ingelheim, NIH, and Sanofi.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
non-opioid pain therapeutics, clinical-stage biopharmaceuticals, immunology drug development, chronic pain treatments, autoimmune disease pipeline
Industry3 codes
PRIMARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Non-opioid Pain Therapeutics
Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Centrexion Therapeutics is a late clinical-stage biopharmaceutical company developing a diversified pipeline of novel, non-opioid medicines for the treatment of chronic pain and an expanding portfolio of immunology and inflammation therapeutics targeting autoimmune diseases. The company operates across two therapeutic areas: a pain pipeline focused on non-opioid therapies and an immunology portfolio addressing indications with high unmet medical needs. Specific drug candidate names are not publicly disclosed, and no products are yet approved or commercialized.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Centrexion Therapeutics is a clinical-stage biopharmaceutical company developing a diversified pipeline of novel, non-opioid clinical stage medicines for the treatment of chronic pain and autoimmune diseases. The company operates across two therapeutic areas: (1) a pain pipeline focused on non-opioid therapies targeting specific types and sources of chronic pain, and (2) an expanding immunology and inflammation portfolio targeting differentiated medicines in indications with high unmet medical needs. The pipeline consists of multiple drug candidates at various clinical stages, though specific product names are not publicly disclosed on the company website. The company leverages its clinical team's track record in autoimmune drug development, including experience with blockbuster and transformative therapies, to advance its programs.

Product and service1 record
1Non-Opioid Pain Pipeline
Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Eli Lilly is listed as a prestigious partner of Centrexion Therapeutics. The partnership focuses on high-value markets with significant unmet need, particularly in non-opioid pain drug development. Governmental and private support for such collaborations is growing as the industry shifts toward non-opioid pain therapeutics.

2Boehringer Ingelheim
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Boehringer Ingelheim is listed as a prestigious partner of Centrexion Therapeutics. The partnership aligns with Centrexion's focus on non-opioid pain relief and immunology medicine development, leveraging Boehringer Ingelheim's resources and expertise in these therapeutic areas.

centrexion.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

NIH is listed as a partner supporting Centrexion Therapeutics' focus on high-value markets with significant unmet need. The collaboration benefits from governmental support for non-opioid pain drug development initiatives.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Sanofi is listed as a prestigious partner of Centrexion Therapeutics, collaborating on focus areas of non-opioid pain relief and immunology. The partnership positions Centrexion among leading pharmaceutical companies committed to addressing significant unmet medical needs.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Boehringer Ingelheim
TypeBroad incumbent
Description

Boehringer Ingelheim is a named Centrexion partner with a global immunology portfolio (including IL-23 and IL-36 programs). It represents the kind of large-cap incumbent with whom Centrexion's immunology assets would most plausibly be partnered or acquired.

TypeDirect peer
Description

Trevena developed oliceridine (Olinvyk), an IV opioid with a differentiated profile, and has historically pursued non-opioid pain mechanisms. It is a direct clinical-stage peer in non-opioid pain development.

TypeDirect peer
Description

Cara is a late-stage biopharma developing difelikefalin (Korsuva) for chronic pruritus and pain in inflammatory conditions. It is a similar-sized, clinical/commercial-stage peer with overlapping pain and immunology positioning.

TypeDirect peer
Description

Pacira is a commercial-stage leader in non-opioid pain management (Exparel, iovera°) and the most established pure-play in the non-opioid pain category. It represents the kind of commercial franchise Centrexion's pipeline could ultimately support or compete with.

TypeDirect peer
Description

Vertex's NaV1.8 inhibitor suzetrigine (Journavx) is the leading first-in-class non-opioid pain therapeutic, approved by FDA in early 2025. Vertex is the most direct competitor in non-opioid pain and the benchmark for the commercial opportunity Centrexion is pursuing.

TypeBroad incumbent
Description

Lilly is a named strategic partner and equity investor in Centrexion, and operates a broad immunology and pain pipeline (including migraine and autoimmune assets) at global scale. It is a likely strategic acquirer and a benchmark for what successful commercial scale-up of Centrexion's assets could look like.

TypeDirect peer
Description

Kiniksa is a clinical-to-commercial immunology-focused biotech developing biologics for autoinflammatory and autoimmune diseases. Its late-stage I&I pipeline and similar scale make it a directly comparable peer to Centrexion's immunology franchise.

TypeBroad incumbent
Description

Sanofi is a named Centrexion partner and one of the largest global immunology companies (Dupixent franchise, multiple autoimmune programs). It is a directly comparable incumbent in the immunology space where Centrexion is building its second therapeutic area.

TypeBroad incumbent
Description

Pfizer is the company Kindler formerly led and remains the largest global pain and immunology incumbent. It is a directly relevant incumbent and a leading candidate to partner with or acquire late-stage non-opioid pain assets.

TypeDirect peer
Description

Collegium is a specialty pain-management company with both branded and non-opioid pain products. It is a direct commercial-stage peer competing for the same physician and payer relationships that any Centrexion launch would target.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds12 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Centrexion Therapeutics

Non-opioid Pain Therapeuticscentrexion.com

Centrexion Therapeutics is a privately held, late clinical-stage biopharmaceutical company developing novel non-opioid therapies for chronic pain and immunology medicines for autoimmune diseases, with partnerships including Eli Lilly, Boehringer Ingelheim, NIH, and Sanofi.

What Centrexion Therapeutics does

Centrexion Therapeutics is a privately held, late clinical-stage biopharmaceutical company founded in 2013 and headquartered at One Boston Place in Boston, Massachusetts. The company is developing a diversified pipeline of novel, non-opioid clinical-stage medicines intended to treat chronic pain by targeting the underlying pathophysiology of pain with specificity to both type and source. It has subsequently expanded into immunology and inflammation, pursuing differentiated therapies for autoimmune diseases characterized by high unmet medical need. Specific drug candidates are not publicly disclosed on the company website, though the pipeline is described as multiple drug candidates at various clinical stages.

The company is led by an experienced biopharmaceutical management team, including former Pfizer Chairman and CEO Jeffrey B. Kindler as CEO, Celgene founder Sol Barer, Ph.D. as Chairman, and Johns Hopkins Professor Emeritus of Neurosurgery James N. Campbell, M.D. as President and Chief Scientific Officer. In 2025 the company transitioned its Chief Medical Officer role, with Randall Stevens, M.D. moving to Chief Medical Strategist and Charles Oh, M.D. joining as CMO. Centrexion maintains strategic co-development partnerships with Eli Lilly, Boehringer Ingelheim, NIH, and Sanofi, and has cumulatively raised approximately $229 million across 12 funding rounds from 2013 through 2020, with investors including New Enterprise Associates, InterWest Partners, 6 Dimensions Capital, ArrowMark Partners, Quan Capital, EFung Capital, Exome Asset Management, and SLR Capital Partners.

Centrexion operates with 11–50 employees and currently serves the United States only. As a clinical-stage company with no approved or commercialized products, it has no disclosed revenue; its business model relies on equity and debt capital to fund R&D, with future commercialization expected to occur via pharmaceutical partnerships and standard pharmaceutical supply chains post-regulatory approval. Pricing of pipeline therapies is not publicly disclosed.

Centrexion Therapeutics firmographics

Firmographics
Name
Centrexion Therapeutics
Legal name
Centrexion Therapeutics Corp.
Website
https://centrexion.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
Centrexion Therapeutics is a privately held, late clinical-stage biopharmaceutical company developing novel non-opioid therapies for chronic pain and immunology medicines for autoimmune diseases, with partnerships including Eli Lilly, Boehringer Ingelheim, NIH, and Sanofi.
Ownership category
akta.pro rank

Centrexion Therapeutics industry classification

Industry
Product category
Non-opioid Pain Therapeutics
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals

Keywords

  • Non-opioid pain therapeutics
  • Clinical-stage biopharmaceuticals
  • Immunology drug development
  • Chronic pain treatments
  • Autoimmune disease pipeline

Where Centrexion Therapeutics is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Centrexion Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Centrexion Therapeutics product offering

Product offering

Core offering

Centrexion Therapeutics is a late clinical-stage biopharmaceutical company developing a diversified pipeline of novel, non-opioid medicines for the treatment of chronic pain and an expanding portfolio of immunology and inflammation therapeutics targeting autoimmune diseases. The company operates across two therapeutic areas: a pain pipeline focused on non-opioid therapies and an immunology portfolio addressing indications with high unmet medical needs. Specific drug candidate names are not publicly disclosed, and no products are yet approved or commercialized.

Product overview

Centrexion Therapeutics is a clinical-stage biopharmaceutical company developing a diversified pipeline of novel, non-opioid clinical stage medicines for the treatment of chronic pain and autoimmune diseases. The company operates across two therapeutic areas: (1) a pain pipeline focused on non-opioid therapies targeting specific types and sources of chronic pain, and (2) an expanding immunology and inflammation portfolio targeting differentiated medicines in indications with high unmet medical needs. The pipeline consists of multiple drug candidates at various clinical stages, though specific product names are not publicly disclosed on the company website. The company leverages its clinical team's track record in autoimmune drug development, including experience with blockbuster and transformative therapies, to advance its programs.

Differentiator

Problem solved

Functional benefit

Products and services

  • Non-Opioid Pain Pipeline

Companies that use Centrexion Therapeutics

Customer profile

Segments3 records

Ideal customer profiles2 records

Centrexion Therapeutics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Centrexion Therapeutics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • Eli Lilly and CompanycoreStrategic or Co-development PartnerEli Lilly is listed as a prestigious partner of Centrexion Therapeutics. The partnership focuses on high-value markets with significant unmet need, particularly in non-opioid pain drug development. Governmental and private support for such collaborations is growing as the industry shifts toward non-opioid pain therapeutics.
  • Boehringer IngelheimcoreStrategic or Co-development PartnerBoehringer Ingelheim is listed as a prestigious partner of Centrexion Therapeutics. The partnership aligns with Centrexion's focus on non-opioid pain relief and immunology medicine development, leveraging Boehringer Ingelheim's resources and expertise in these therapeutic areas.
  • National Institutes of Health (NIH)coreStrategic or Co-development PartnerNIH is listed as a partner supporting Centrexion Therapeutics' focus on high-value markets with significant unmet need. The collaboration benefits from governmental support for non-opioid pain drug development initiatives.
  • SanoficoreStrategic or Co-development PartnerSanofi is listed as a prestigious partner of Centrexion Therapeutics, collaborating on focus areas of non-opioid pain relief and immunology. The partnership positions Centrexion among leading pharmaceutical companies committed to addressing significant unmet medical needs.

Recent moves6 records

Expansion highlights5 records

Centrexion Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • Boehringer Ingelheim: Boehringer Ingelheim is a named Centrexion partner with a global immunology portfolio (including IL-23 and IL-36 programs). It represents the kind of large-cap incumbent with whom Centrexion's immunology assets would most plausibly be partnered or acquired.
  • Eli Lilly and Company: Lilly is a named strategic partner and equity investor in Centrexion, and operates a broad immunology and pain pipeline (including migraine and autoimmune assets) at global scale. It is a likely strategic acquirer and a benchmark for what successful commercial scale-up of Centrexion's assets could look like.
  • Sanofi: Sanofi is a named Centrexion partner and one of the largest global immunology companies (Dupixent franchise, multiple autoimmune programs). It is a directly comparable incumbent in the immunology space where Centrexion is building its second therapeutic area.
  • Pfizer: Pfizer is the company Kindler formerly led and remains the largest global pain and immunology incumbent. It is a directly relevant incumbent and a leading candidate to partner with or acquire late-stage non-opioid pain assets.

Direct peers

  • Trevena: Trevena developed oliceridine (Olinvyk), an IV opioid with a differentiated profile, and has historically pursued non-opioid pain mechanisms. It is a direct clinical-stage peer in non-opioid pain development.
  • Cara Therapeutics: Cara is a late-stage biopharma developing difelikefalin (Korsuva) for chronic pruritus and pain in inflammatory conditions. It is a similar-sized, clinical/commercial-stage peer with overlapping pain and immunology positioning.
  • Pacira BioSciences: Pacira is a commercial-stage leader in non-opioid pain management (Exparel, iovera°) and the most established pure-play in the non-opioid pain category. It represents the kind of commercial franchise Centrexion's pipeline could ultimately support or compete with.
  • Vertex Pharmaceuticals: Vertex's NaV1.8 inhibitor suzetrigine (Journavx) is the leading first-in-class non-opioid pain therapeutic, approved by FDA in early 2025. Vertex is the most direct competitor in non-opioid pain and the benchmark for the commercial opportunity Centrexion is pursuing.
  • Kiniksa Pharmaceuticals: Kiniksa is a clinical-to-commercial immunology-focused biotech developing biologics for autoinflammatory and autoimmune diseases. Its late-stage I&I pipeline and similar scale make it a directly comparable peer to Centrexion's immunology franchise.
  • Collegium Pharmaceutical: Collegium is a specialty pain-management company with both branded and non-opioid pain products. It is a direct commercial-stage peer competing for the same physician and payer relationships that any Centrexion launch would target.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Centrexion Therapeutics social profiles

Digital presence

Centrexion Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Centrexion Therapeutics leadership team

Management profile

Number of profiles

Profiles13 records

Centrexion Therapeutics funding detail

Funding detail

Funding overview

Funding rounds12 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Centrexion Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Centrexion Therapeutics

What does Centrexion Therapeutics do?

Centrexion Therapeutics is a late clinical-stage biopharmaceutical company developing a diversified pipeline of novel, non-opioid medicines for the treatment of chronic pain and an expanding portfolio of immunology and inflammation therapeutics targeting autoimmune diseases. The company operates across two therapeutic areas: a pain pipeline focused on non-opioid therapies and an immunology portfolio addressing indications with high unmet medical needs. Specific drug candidate names are not publicly disclosed, and no products are yet approved or commercialized.

Is Centrexion Therapeutics a public or private company?

Centrexion Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Centrexion Therapeutics founded?

Centrexion Therapeutics was founded in 2013. It employs 11 to 50 people.

Where is Centrexion Therapeutics based?

Centrexion Therapeutics is headquartered in Boston, United States, in the North America region.

Who are Centrexion Therapeutics's main competitors?

Broad incumbents on record are Boehringer Ingelheim, Eli Lilly and Company, Sanofi and Pfizer. Direct peers are Trevena, Cara Therapeutics, Pacira BioSciences, Vertex Pharmaceuticals, Kiniksa Pharmaceuticals and Collegium Pharmaceutical.

Does Centrexion Therapeutics have an API?

No public API is recorded for Centrexion Therapeutics.

What industry is Centrexion Therapeutics in?

Centrexion Therapeutics's product category is Non-opioid Pain Therapeutics. Its primary akta.pro industry code is HLAIAAAN, Pain Management & Anesthesiology Pharmaceuticals, with a secondary code of HLAIAAAD, Immunology & Inflammation Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Tracxn2026 Investor Profile, Portfolio, Team & Investment TrendsThe article presents a curated list of investor profiles and portfolio companies, specifically highlighting Namma Yatri, NeuroCare Group, and Centrexion with their respective financial and operational metrics. It details key facts for each entity, including founding years, locations, funding stages, total capital raised, and employee counts as of late 2025 or early 2026. The content serves as a directory of investment opportunities across digital mobility, neurotechnology, and pain management sectors.PR NewswireEmerging Non-Opioid Pharmaceuticals for Pain Management, 2020: Focus on Neuropathic Pain, Migraine, Post-Surgical Pain, Cancer Pain, Chronic PainResearch and Markets has added a new report titled "Emerging Non-Opioid Pharmaceuticals for Pain Management, 2020" to its catalog of offerings. The publication analyzes technological advances in non-opioid treatments for conditions such as neuropathic pain, migraine, and cancer pain, while providing competitive intelligence on emerging innovators like Centrexion Therapeutics and Xenon Pharmaceuticals. It also covers the patent landscape and growth opportunities within the non-narcotic pain therapy sector.WsjCentrexion Therapeutics, Eli Lilly Strike Nearly $1 Billion Licensing DealEli Lilly paid $47.5 million cash to secure rights to Centrexion's non-opioid pain drug CNTX-0290, which targets the SSTR4 receptor. The deal includes up to $950 million in milestone payments, with the drug in early clinical trials for chronic pain.FierceBiotechCentrexion farms out pain drug to Lilly for $47.5M and could reap much moreEli Lilly has paid $47.5 million upfront to license Centrexion Therapeutics' phase 1 non-opioid pain drug, CNTX-0290, gaining exclusive worldwide rights to the asset. Under the agreement, Centrexion is eligible for up to $575 million in development and regulatory milestones, plus an additional $375 million if the drug successfully reaches the market. This collaboration marks a significant strategic step for Centrexion as it advances its pipeline of novel chronic pain therapies.PR NewswireLilly Announces Licensing Agreement for Non-Opioid Pain Asset from Centrexion TherapeuticsEli Lilly and Company announced a licensing agreement to acquire exclusive worldwide rights for CNTX-0290 from Centrexion Therapeutics Corporation for an upfront payment of $47.5 million. The drug candidate is a novel small molecule SSTR4 agonist currently in Phase 1 clinical testing as a potential non-opioid treatment for chronic pain conditions, with Centrexion eligible for up to $575 million in development and regulatory milestones, plus up to $375 million in sales milestones and tiered royalties upon commercialization. Both companies may elect to co-promote the asset in the U.S. pending regulatory success.PR NewswireAccelerating Development of Non-Opioid Pain MedicinesThe fourth annual American Pain Society Conference on Analgesic Trials (APS-CAT) was held to accelerate development of non-opioid pain medicines by improving clinical trial design and conduct, bringing together industry experts, academicians, and regulatory officials. According to HHS data cited in the article, 2.1 million people in the United States experienced an opioid use disorder in 2017, with over 43,000 dying from opioid overdoses. Executives from multiple pharmaceutical and consulting companies including Heron Therapeutics, Flexion Therapeutics, and Centrexion Therapeutics shared perspectives on scientific, regulatory, and economic challenges in developing non-opioid analgesics.PR.comCo-Chairs Centrexion Therapeutics & Metys Pharmaceuticals Send Invites to SMi’s 19th Annual Pain Therapeutics - PR.comSMi will host its 19th Annual Pain Therapeutics Conference in London on May 13-14, 2019, co-chaired by Centrexion Therapeutics and Metys Pharmaceuticals. The event will cover new therapies and clinical trial methodologies, with the co-chairs noting recent regulatory approvals for CGRP migraine drugs and $500M in NIH funding.GlobeNewswireCentrexion Therapeutics Announces CNTX-4975 Preclinical and Clinical Data Presentations at the 35th Annual American Academy of Pain Medicine MeetingCentrexion Therapeutics Corporation announced that it will present two posters on CNTX-4975 at the 35th Annual American Academy of Pain Medicine Meeting, held from March 6-10, 2019 in Denver, Colorado. The presentations will cover data on efficacy, safety, and pharmacokinetics from preclinical and clinical trials for the treatment of moderate to severe knee osteoarthritis pain. CNTX-4975 has shown promising results with substantial pain reduction lasting up to six months following treatment.PR.comGreat Time for Pain Research: SMi’s Exclusive Interviews with Lotus Clinical Research and Centrexion Therapeutics - PR.comSMi Group interviewed Lotus Clinical Research and Centrexion Therapeutics executives ahead of the Pain Therapeutics Conference in London. Kerrie Brady and Randall Stevens highlighted translation from preclinical to clinical success as a key challenge, while Neil Singla cited the opioid crisis as driving interest in new analgesic therapies.